Public investors are betting big on biotechs, and Inhibrx is looking to capitalize on the industry’s recent resurgence of initial public offerings.
The La Jolla, CA-based company, which is developing drugs for cancer and a rare respiratory disease, has again applied for a listing on the Nasdaq, a filing that comes more than a year after it first outlined an IPO plan. It quietly withdrew that proposal last November.
In its second run at the public markets, Inhibrix has set a preliminary $100 million IPO goal, up by about one-third from the target it set last year. The company has… Read more »
UNDERWRITERS AND PARTNERS
